Component

CXCL10

Interferon-inducible chemokine and ligand of CXCR3.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Molecular dynamics simulations indicated lariciresinol was a high-affinity ligand for CXCL10.

    Lariciresinol, enantiomer unresolved → CXCL10 source_derived_draftungraded
    Experimental context and source evidence
    duration
    Not applicable
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    experimental_model
    Molecular docking and molecular dynamics simulation
    exposure
    Lariciresinol, selected among gut microbiota metabolites in a network analysis
    limitations
    A simulated binding result. The study is computational with unspecified in vitro validation and its authors describe it as hypothesis-generating; no cell line, knockdown or binding measurement is reported in the abstract.
    organism
    Molecular docking and molecular dynamics simulation
    plain_language
    Molecular dynamics simulations indicated lariciresinol was a high-affinity ligand for CXCL10.
    primary_references
    Integrative multi-omics analysis identifies CXCL10 as a gut microbiota-associated target in breast cancer. (2025). https://pubmed.ncbi.nlm.nih.gov/41298864/ DOI: 10.1186/s13568-025-01989-0
    route
    In silico
    tissue
    Ligand binding to a chemokine

    Lariciresinol: five molecules under one name, and the mechanisms each one carries (2026-09-22) · lines 242–251

    Original AI-assisted curation of twelve primary studies, every abstract read and all DOIs cross-checked against live PubMed metadata. Mechanism edges only, with no conclusion or claim of benefit recorded. Three author clusters account for eight of the twelve and carry shared laboratory keys. Study-specific concentrations, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft

    ## lariciresinol-binds-cxcl10 Molecular dynamics simulations indicated lariciresinol was a high-affinity ligand for CXCL10. Model/species: Molecular docking and molecular dynamics simulation Tissue/system: Ligand binding to a chemokine Exposure: Lariciresinol, selected among gut microbiota metabolites in a network analysis Route: In silico Duration: Not applicable Limits: A simulated binding result. The study is computational with unspecified in vitro validation and its authors describe it as hypothesis-generating; no cell line, knockdown or binding measurement is reported in the abstract. Primary reference: Integrative multi-omics analysis identifies CXCL10 as a gut microbiota-associated target in breast cancer. (2025). https://pubmed.ncbi.nlm.nih.gov/41298864/ DOI: 10.1186/s13568-025-01989-0 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards